je.st
news
Tag: evaluating
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
2014-10-08 17:13:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the companys investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place at the John B. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
data
present
american
Evaluating The Spin-Off ETF
2014-09-19 02:51:24| Paper - Topix.net
The indiscriminate selling of the shares of the spin-off by both retail and institutional investors results in pronounced undervaluation of the stock. Retail investors do not want to own a company they did not choose, while many funds are forced to sell the new stock, as it does not fit their criteria.
Tags: evaluating
etf
spinoff
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab
2014-09-03 05:50:17| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology 2014 in Madrid, Spain, September 26 - 30. Data on pembrolizumab are ... (more)
Tags: data
present
types
studies
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
2014-09-02 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
types
studies
Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
2014-08-26 16:20:33| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Agreement to Combine Mercks Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizers crizotinib (XALKORI) in Clinical Trial WHITEHOUSE STATION, N.J. Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizers crizotinib (XALKORI) with Mercks investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Language: English read more
Tags: study
combination
evaluating
collaborate
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »